🇺🇸 FDA
Patent

US 10220029

Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases

granted A61KA61K31/454A61P

Quick answer

US patent 10220029 (Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases) held by OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES” expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES”
Grant date
Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/454, A61P, A61P1/00, A61P1/04